Sponsor Pipeline

Antengene Biologics Limited Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
3
Active Trials
2
Recruiting
2
Disease Areas
What Changed in the Last 30 Days
First PostedNew Trial FilingPhaseStatus
2026-07-28 NCT07732309 A Study of ATG-201 in Adult Participants With Autoimmune Diseases Phase 1 Not Yet Recruiting
Active Trials by Phase
Phase 1/2
1
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 1/2
NCT07327229 A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in… Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Recruiting
Phase 1
NCT05718895 A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors Advanced/Metastatic Solid Tumors Recruiting
NCT07732309 A Study of ATG-201 in Adult Participants With Autoimmune Diseases Systemic Lupus Erythematosus Not Yet Recruiting
Disease Areas
Lupus (SLE) (1) Scleroderma (1)
Get alerts when Antengene Biologics Limited's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free